MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Autor: Dreno B; Department of Dermatooncology, Hotel Dieu Nantes University Hospital, Nantes, France., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Smithers BM; Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia., Santinami M; Melanoma Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Jouary T; Service d'Oncologie Médicale, Hôpital François Mitterrand, Pau, France., Gutzmer R; Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany., Levchenko E; Petrov Research Institute of Oncology, St Petersburg, Russia., Rutkowski P; Department of Soft Tissue, Bone Sarcoma, and Melanoma, Maria Sklodowska-Curie Institute, Oncology Center, Warsaw, Poland., Grob JJ; Department of Dermatology and Skin Cancers, La Timone APHM Hospital, Aix-Marseille University, Marseille, France., Korovin S; Department of Skin and Soft Tissue Tumours, National Cancer Institute, Kiev, Ukraine., Drucis K; Swissmed Centrum Zdrowia, Gdansk, Poland; Department of Surgical Oncology, Gdansk Medical University, Gdansk, Poland., Grange F; Dermatology Department, Hôpital Robert Debré, Université de Reims Champagne-Ardenne, Reims, France., Machet L; Department of Dermatology, Centre Hospitalier Universitaire, Tours, France; UFR de Médecine, Université François-Rabelais, Tours, France., Hersey P; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia., Krajsova I; Dermato-oncology Department, General University Hospital, Prague, Czech Republic., Testori A; Columbus Clinic Center, Milan, Italy., Conry R; Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Guillot B; Département de Dermatologie, Centre Hospitalier Universitaire, Hôpital Saint-Éloi, Montpellier, France., Kruit WHJ; Department of Medical Oncology, Erasmus MC Cancer institute, Rotterdam, Netherlands., Demidov L; Cancer Research Center, Moscow, Russia., Thompson JA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA., Bondarenko I; Department of Oncology and Medical Radiology, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine., Jaroszek J; Centrum Medyczne Bieńkowski, Klinika Chirurgii Plastycznej, Bydgoszcz, Poland; Department of Oncological Surgery, Oncology Center, Bydgoszcz, Poland., Puig S; Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain., Cinat G; Instituto de Oncología Ángel H Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina., Hauschild A; Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany., Goeman JJ; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands., van Houwelingen HC; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands., Ulloa-Montoya F; GlaxoSmithKline, Rixensart, Belgium. Electronic address: fernando.x.ulloa-montoya@GSK.com., Callegaro A; GlaxoSmithKline, Rixensart, Belgium., Dizier B; GlaxoSmithKline, Rixensart, Belgium; Immunology Translational Medicine, UCB, Brussels, Belgium., Spiessens B; GlaxoSmithKline, Rixensart, Belgium; Biostatistics Department, Janssen Research & Development, Beerse, Belgium., Debois M; GlaxoSmithKline, Rixensart, Belgium., Brichard VG; GlaxoSmithKline, Rixensart, Belgium; ViaNova Biosciences, Brussels, Belgium., Louahed J; GlaxoSmithKline, Rixensart, Belgium., Therasse P; GlaxoSmithKline, Rixensart, Belgium; Laboratoires Servier, Paris, France., Debruyne C; GlaxoSmithKline, Rixensart, Belgium; University Hospitals Leuven, Leuven, Belgium., Kirkwood JM; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2018 Jul; Vol. 19 (7), pp. 916-929. Date of Electronic Publication: 2018 Jun 13.

Immunotherapy of Diseases and Nanotechnology: Current State and Prospects.

Autor: Piminov, O. F., Sahaidak-Nikitiuk, R. V., Kvitchata, A. I., Rolik-Attia, S. M.

Publikováno v: Journal of Organic & Pharmaceutical Chemistry / Zhurnal Organichnoi ta Farmatsevtichnoi Khimii; 2024, Vol. 22 Issue 1, p13-21, 9p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Heterogeneity of the tumor immune microenvironment and clinical interventions.

Autor: Jin, Zheng, Zhou, Qin, Cheng, Jia-Nan, Jia, Qingzhu, Zhu, Bo

Publikováno v: Frontiers of Medicine; Aug2023, Vol. 17 Issue 4, p617-648, 32p

POLSCY SYNDONOLODZY. Z DZIEJÓW BADAŃ CAŁUNU TURYŃSKIEGO I ICH POPULARYZACJI.

Autor: PILARCZYK, KRZYSZTOF

Publikováno v: Collectanea Theologica. 2018, Vol. 88 Issue 2, p17-63. 47p.